Deargen

Deargen is an AI-First Pharmatech Company with a focus on sequence-based drug discovery and development. Founded in 2016 and headquartered in South Korea, Deargen aims to revolutionize the drug development process by integrating advanced AI technology and expert experience. The company's end-to-end AI solution allows for the discovery, design, and development of drugs in the fastest and most effective manner, saving time and costs compared to traditional methods. Deargen's expertise lies in Hit/Lead compound discovery irrespective of the target protein’s 3D information, achieved by integrating transformer technology into the pharmaceutical field. The team comprises experts in drug development, deep learning, software, biology, computational & medicinal chemistry, enabling target discovery to lead optimization. The recent KRW20.00B Series B investment on 24 February 2022 indicates strong investor interest in Deargen's AI-driven approach. Notable investors include Korea Development Bank, TS Investment, Hana Ventures, Nvestor (Korea), The Wells Investment. Deargen's commitment to meeting unmet scientific needs through technology and experience positions the company as a promising player in the Biotechnology industry.